CD274 and non-small cell lung carcinoma: In the first‐line treatment of NSCLC, pembrolizumab has shown clinical efficacy both when administered as monotherapy to advanced NSCLC patients with programmed death‐ligand 1 (PD‐L1) tumor proportion score (TPS) ≥50% and ≥1%, and when administered in combination with platinum‐doublet chemotherapy to all NSCLC patients regardless of PD‐L1 expression in tumor cells.